Improve gait using transcranial stimulation
- Trial ID
- NCT06324448
- Official Title
- Self-administered Transcranial Direct Current Stimulation for Improving Single- and Dual-task Gait in Patients With Idiopathic Parkinson's Disease: A Prospective, Single-center, Double-blind, Exploratory, Randomized Controlled Trial
- Goal
- Improve gait using transcranial stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Seoul National University Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 24 participants
- Conditions
- Parkinson Disease
- Interventions
- Transcranial direct current stimulation
Plain-Language Summary
The goal is to see whether self-applied transcranial direct current stimulation, a low-intensity electrical current delivered through the scalp, can improve walking and walking while multitasking in people with idiopathic Parkinson's disease. The approach uses a portable tDCS device to gently boost or modulate motor cortex excitability to strengthen motor control, it is used alongside usual Parkinson's medications without changing them, and participants are trained to administer the stimulation themselves in a randomized, double-blind setup. The study is looking for about 24 adults aged 19 and older with idiopathic PD at Hoehn and Yahr stages 2, 2.5, or 3 who meet Korean-MoCA cognitive cutoffs and do not have seizures, certain metal implants, skin problems at the stimulation site, severe dyskinesia or on-off fluctuations, planned medication changes, pregnancy, or other major conditions affecting gait.
Locations
- Seoul National University Hospital, Seoul, Seoul, South Korea
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Transcranial direct current stimulation. The goal is to see whether self-applied transcranial direct current stimulation, a low-intensity electrical current delivered through the scalp, can improve walking and walking while multitasking in people with idiopathic Parkinson's disease. The approach uses a portable tDCS device to gently boost or modulate motor cortex excitability to strengthen motor control, it is used alongside usual Parkinson's medications without changing them, and participants are trained to administer the stimulation themselves in a randomized, double-blind setup. The study is looking for about 24 adults aged 19 and older with idiopathic PD at Hoehn and Yahr stages 2, 2.5, or 3 who meet Korean-MoCA cognitive cutoffs and do not have seizures, certain metal implants, skin problems at the stimulation site, severe dyskinesia or on-off fluctuations, planned medication changes, pregnancy, or other major conditions affecting gait.
- Who can participate?
- Participants must be at least 19 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years.